Latest research shows how cancer cells react to chemotherapy

July 14, 2011, CORDIS
Latest research shows how cancer cells react to chemotherapy

EU-funded researchers have made good progress in understanding how cancer cells can sometimes resist the effects of chemotherapy. This new knowledge will move forward the development of increasingly effective cancer treatments and could go some way to reducing relapse, good news for cancer patients and scientists alike.

As part of the APO-SYS ('Apoptosis systems biology applied to cancer and AIDS') project, which received a funding boost of EUR 11 million under the 'Health' Theme of the (FP7), the team of researchers from the Dublin-based Royal College of Surgeons in Ireland (RCSI) carried out a comprehensive study of .

Writing in the journal Molecular , the team explain how their findings show that chemotherapy resistance occurs due to metabolism differences between cancer cells and normal .

In chemotherapy, anti-cancer drugs are used to kill cancer cells. They do this by stimulating a process of called apoptosis, as well as hindering the function of the mitochondria. The mitochondria is responsible for regulating cell energy production and maintaining a balance of water and ions; therefore, if the mitochondria is paralysed, the whole cell cannot function.

However, in addition to producing energy in the mitochondria, cancer cells can also produce energy by using glucose in a process known as glycolysis.

Although previous studies have shown that the process of glycolysis can effectively bring cancer cells being targeted by chemotherapy 'back to life', the Irish team has now found that also helps to restore mitochondrial function, meaning that cancer cells may continue to function following the treatment.

This study, which was based on computational modelling and live cell microscopy, brings scientists closer to understanding why and how some cancer cells survive both apoptosis and mitochondria impairment.

Dr. Heinrich Huber, lead researcher on the study from the RCSI, says: 'Our findings show that when cancer cells are exposed to elevated glucose levels, mitochondrial function can be restored and osmotic homeostasis can be maintained, which contributes to resistance to chemotherapy. Therefore, we have found that in order for cancer treatments to be effective, they must target the cancer cell's ability to produce energy by using glucose within its fluids as well as destroying the mitochondria. It is also important that glucose levels in patients are monitored because this can be a factor in resistance to treatment.'

According to figures from the World Health Organization (WHO), cancer is one of the main causes of death worldwide and was responsible for 7.6 million deaths (approximately 13 % of all deaths) in 2008. The WHO also estimates that this figure will rise to over 11 million by 2030.

As understanding the mechanistic details of how cancer cells are able to resist chemotherapy can provide strategies to increase treatment efficiency and reduce clinical relapse, the team hope their research will lead to further discoveries in and go some way towards reducing the worldwide impact of this killer condition.

The APO-SYS project, which runs until 2012, brings together a pan-European consortium of experimental biologists, biomathematicians, biostatisticians, computer scientists and clinical scientists, all working on cell death pathways in health and disease, with a particular focus on cancer and AIDS.

Explore further: Research identifies how cancer cells cheat death

More information: Huber, H. J., et al. (2011) Glucose metabolism determines resistance of cancer cells to bioenergetic crisis after cytochrome-c release. Molecular Systems Biology. DOI: 10.1038/msb.2011.2

Related Stories

Research identifies how cancer cells cheat death

June 8, 2011
Research led by David Litchfield of The University of Western Ontario has identified how biochemical pathways can be "rewired" in cancer cells to allow these cells to ignore signals that should normally trigger their death. ...

Recommended for you

New therapeutic gel shows promise against cancerous tumors

February 21, 2018
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results ...

Kinase inhibitor larotrectinib shows durable anti-tumor abilities

February 21, 2018
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors ...

Five novel genetic changes linked to pancreatic cancer risk

February 21, 2018
In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center and the National Cancer Institute, and collaborators from over 80 other ...

Similarities found in cancer initiation in kidney, liver, stomach, pancreas

February 21, 2018
Recent research at Washington University School of Medicine in St. Louis demonstrated that mature cells in the stomach sometimes revert back to behaving like rapidly dividing stem cells. Now, the researchers have found that ...

Research could change how doctors treat leukemia and other cancers fed by fat

February 21, 2018
Obesity and cancer risk have a mysterious relationship, with obesity increasing the risk for 13 types of cancer. For some cancers—including pediatric cancers—obesity affects survival rates, which are lower for people ...

New technique predicts gene resistance to cancer treatments

February 21, 2018
Yale School of Public Health researchers have developed a new method to predict likely resistance paths to cancer therapeutics, and a methodology to apply it to one of the most frequent cancer-causing genes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.